newsfilter
← Latest News
PR Newswire·

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

Results presented across UCB's generalized myasthenia gravis (gMG) development program builds the body of evidence around the complexities of gMG Presentations to include data from the Phase 3 MycarinG study of rozanolixizumab as well as the Phase 3 RA